Adjuvant Capecitabine Plus Oxaliplatin Following D2 Gastrectomy May Be Effective for Gastric Cancer
the Cancer Therapy Advisor take:
According to a new study published in the journal The Lancet Oncology, adjuvant capecitabine in combination with oxaliplatin after undergoing a D2 gastrectomy is a viable option for patients with operable stage 2 or 3 gastric cancer.
For the phase 3, open-label CLASSIC trial, researchers sought to investigate whether adjuvant capecitabine plus oxaliplatin compared with observation after D2 gastrectomy improves survival in patients with stage 2 or 3 gastric cancer.
Researchers randomly assigned 1,035 patients with stage 2-3B gastric cancer who underwent curative D2 gastrectomy to receive either adjuvant chemotherapy or observation. Participants that received chemotherapy received eight 3-week cycles of capecitabine 1,000mg/m2 twice daily for 2 weeks and oxaliplatin 130mg/m2 on day 1.
Results showed that 27% of patients in the adjuvant chemotherapy group achieved a 3-year disease-free survival compared with 39% among those that received observation only (HR = 0.58, 95% CI, 0.47 - 0.72; P < 0.0001).
Among those in the chemotherapy group, 68% were estimated to achieve a 5-year disease-free survival versus 53% in the observation group. Estimated 5-year overall survival rates were 78% and 69% in the adjuvant chemotherapy group and observation group, respectively.
Adjuvant capecitabine with oxaliplatin after gastrectomy is a viable option.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- FDA Approves Ivosidenib for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia
- Clinical Stage at First Response May Predict Outcomes in Chronic Lymphocytic Leukemia
- Exercise and Cancer
- Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer
- Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer